{"id":34498,"date":"2025-07-14T08:01:00","date_gmt":"2025-07-14T06:01:00","guid":{"rendered":"https:\/\/ggba.swiss\/?p=34498"},"modified":"2025-07-14T12:03:33","modified_gmt":"2025-07-14T10:03:33","slug":"addex-therapeutics-leads-chf-2-million-investment-in-stalicla","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/","title":{"rendered":"Addex Therapeutics leads CHF 2 million investment in Stalicla"},"content":{"rendered":"\n<p>Geneva\u2019s life sciences ecosystem continues to gain momentum as <a href=\"https:\/\/stalicla.com\/\">Stalicla SA<\/a>, a clinical-stage biopharmaceutical company developing precision medicine treatments for neurodevelopmental and neuropsychiatric disorders, has secured CHF 2 million in a financing round led by fellow Geneva-based company <a href=\"https:\/\/www.addextherapeutics.com\/en\/\">Addex Therapeutics<\/a>. The investment will sustain Stalicla\u2019s operations and support the progression of its clinical programs as it prepares for a Series C financing round.<\/p>\n\n\n\n<p>Founded with a focus on precision medicine in complex brain disorders, Stalicla has developed a proprietary platform, DEPI (Databased Endophenotyping Precision Identification), designed to identify biologically defined patient subgroups within heterogeneous conditions like autism spectrum disorder (ASD). The company is preparing to launch Phase 2 trials for its lead assets, STP1 and STP2, both targeting stratified subpopulations within ASD. In parallel, STP7 (Mavoglurant) is advancing toward Phase 3, following a Phase 3-enabling drug-drug interaction study completed in October 2024 and funded by the US NIH\u2013National Institute on Drug Abuse.<\/p>\n\n\n\n<p>As part of the investment agreement, Tim Dyer, CEO of Addex Therapeutics, has joined Stalicla\u2019s Board of Directors and has been appointed Chairman. \u201cStalicla has built a world-leading precision medicine platform for neurodevelopmental disorders,\u201d Dyer stated, highlighting the company\u2019s clinical-stage portfolio and its STP7 program, aimed at addressing substance use disorders.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A hub for neurotherapeutic innovation<\/h4>\n\n\n\n<p>The collaboration reflects growing synergies within Geneva\u2019s neuroscience innovation landscape. In April 2024, <a href=\"https:\/\/ggba.swiss\/en\/addex-therapeutics-launches-spin-off-neurosterix-in-geneva-with-usd-63-million-investment\/\">Addex itself launched the spin-off Neurosterix<\/a>, in partnership with US-based Perceptive Advisors, to accelerate the development of allosteric modulators for neurological diseases. The CHF 2 million investment in Stalicla aligns with Addex\u2019s broader strategy to support promising neurotherapeutic platforms.<\/p>\n\n\n\n<p>\u201cThis financing is a key step in securing our runway to reach a number of important milestones,\u201d said Lynn Durham, CEO of Stalicla. \u201cWe are grateful for the support from the Addex-led syndicate, which enables us to continue advancing our precision medicine programs.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.<\/p>\n","protected":false},"author":6,"featured_media":34499,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,930,890,918,940,902],"class_list":["post-34498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-digital-health","tag-healthcare","tag-investment","tag-neuroscience","tag-personalized-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex Therapeutics leads CHF 2 million investment in Stalicla<\/title>\n<meta name=\"description\" content=\"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex Therapeutics leads CHF 2 million investment in Stalicla\" \/>\n<meta property=\"og:description\" content=\"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T06:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T10:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Addex Therapeutics leads CHF 2 million investment in Stalicla\",\"datePublished\":\"2025-07-14T06:01:00+00:00\",\"dateModified\":\"2025-07-14T10:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\"},\"wordCount\":312,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Digital Health\",\"Healthcare\",\"Investment\",\"Neuroscience\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\",\"url\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\",\"name\":\"Addex Therapeutics leads CHF 2 million investment in Stalicla\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"datePublished\":\"2025-07-14T06:01:00+00:00\",\"dateModified\":\"2025-07-14T10:03:33+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Stalicla applies precision medicine to neurodevelopmental disorders by targeting specific subgroups through its proprietary platform. | \u00a9 Stalicla\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex Therapeutics leads CHF 2 million investment in Stalicla\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex Therapeutics leads CHF 2 million investment in Stalicla","description":"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/","og_locale":"en_US","og_type":"article","og_title":"Addex Therapeutics leads CHF 2 million investment in Stalicla","og_description":"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.","og_url":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-07-14T06:01:00+00:00","article_modified_time":"2025-07-14T10:03:33+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Addex Therapeutics leads CHF 2 million investment in Stalicla","datePublished":"2025-07-14T06:01:00+00:00","dateModified":"2025-07-14T10:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/"},"wordCount":312,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","keywords":["Biotech","Digital Health","Healthcare","Investment","Neuroscience","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/","url":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/","name":"Addex Therapeutics leads CHF 2 million investment in Stalicla","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","datePublished":"2025-07-14T06:01:00+00:00","dateModified":"2025-07-14T10:03:33+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","width":1180,"height":811,"caption":"Stalicla applies precision medicine to neurodevelopmental disorders by targeting specific subgroups through its proprietary platform. | \u00a9 Stalicla"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Addex Therapeutics leads CHF 2 million investment in Stalicla"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=34498"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34498\/revisions"}],"predecessor-version":[{"id":34502,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34498\/revisions\/34502"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/34499"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=34498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=34498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=34498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}